News

A leader in plant-based biotechnology, iBio, Inc. announced a key new U.S. patent, called “Yersinia pestis Antigens, Vaccine Compositions and Related Methods.” It includes plague antigens that work with the Company’s iBioModulator™ thermostable immunomodulator protein. The technology is directed at providing protection against pneumonic plague, which could be used as a potential form…

Idiopathic pulmonary fibrosis (IPF) is a rare lung condition that mainly causes scarring of the lungs, with symptoms including shortness of breath and persistent dry cough. IPF is a progressive and potentially fatal condition with an unknown cause. At the moment, available treatments are only symptomatic, and much more…

The Department of Veterans Affairs recently completed a randomized controlled-trial aimed to test the efficacy of an interventional pulmonary rehabilitation-structured exercise program for patients with Idiopathic Pulmonary Fibrosis. The incidence and prevalence of Idiopathic Pulmonary Fibrosis (IPF) progressively increases with age, being mostly reflected in older males. Risk factors…

The University of Alabama at Birmingham recently reacted to news of its inclusion into the Pulmonary Fibrosis Foundation Care Center Network, stating that it is an honor in recognition of their commitment towards patients who suffer from pulmonary fibrosis (PF), and that being an official PFFCC will allow them to…

The Pulmonary Fibrosis Foundation (PFF), a trusted resource for the pulmonary fibrosis (PF) community committed to raising awareness, providing disease education, and funding research for this debilitating disease, has just announced it has accredited a dozen new PFF Care Centers, bringing the total number of centers under the…

Boehringer Ingelheim, a leader in developing treatments for lung diseases, sponsored a phase 2 clinical trial investigating four doses of BIBF 1120 (nintedanib) in patients with idiopathic pulmonary fibrosis. The primary goal of “Safety…

In a recent study entitled “Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis,” a team of researchers show acute exacerbations in idiopathic pulmonary fibrosis are caused by multifactorial cellular responses, including macrophage activation. The study was published in the open access journal…

Pulmonary fibrosis may run in the family, based on the frequent occurrence of this disorder in people who are related, according to an article titled Familial Pulmonary Fibrosis recently published in Revue des Maladies Respiratoires by a group from the Centre de Compétence Maladies Rares Pulmonaires, Hôpital…

The European Commission (EC) has approved Boehringer Ingelheim‘s application for the commercialization of the drug nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF), within the European Union. Under the brand name Ofev, the drug therapy was approved by the EC due to…

A study published this week in The Journal of Molecular Medicine Reports  discussed the discovery of biological mechanisms that may have important implications in the future treatment of idiopathic pulmonary fibrosis (IPF). The research was conducted by an international team of collaborating scientists from the University…